Q3 2021 13F Holders as of 9/30/2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
126M
-
Number of holders
-
129
-
Total 13F shares, excl. options
-
55.5M
-
Shares change
-
-1.88M
-
Total reported value, excl. options
-
$323M
-
Value change
-
-$27M
-
Put/Call ratio
-
4.61
-
Number of buys
-
67
-
Number of sells
-
-61
-
Price
-
$5.82
Significant Holders of Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) as of Q3 2021
170 filings reported holding KPTI - Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share as of Q3 2021.
Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) has 129 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 55.5M shares
of 126M outstanding shares and own 43.9% of the company stock.
Largest 10 shareholders include BlackRock Inc. (8.79M shares), STATE STREET CORP (8.02M shares), Palo Alto Investors LP (5.38M shares), VANGUARD GROUP INC (3.64M shares), Rubric Capital Management LP (3.38M shares), Delphi Management Partners VIII, L.L.C. (2.26M shares), ALKEON CAPITAL MANAGEMENT LLC (1.96M shares), Lombard Odier Asset Management (Switzerland) SA (1.52M shares), GEODE CAPITAL MANAGEMENT, LLC (1.41M shares), and RICE HALL JAMES & ASSOCIATES, LLC (1.4M shares).
This table shows the top 129 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.